Outcome of Board meeting of the Company HELD TODAY I.E 05TH MAY 2025 : (i) Audited Standalone Financial Results for the Fourth quarter and year ended 31st March, 2025; (ii) Audited ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.7 pts more than Nifty Microcap 250 and 5.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Smruthi Organics Ltd's Board, at its meeting on May 5, 2025, approved the audited standalone financial results for Q4 FY25 and the full year ended March 31, 2025, along with the balance sheet and cash flow statement. Statutory auditors M/s Gokhale & Sathe issued an unmodified (clean) opinion on the results. For FY25, revenue from operations stood at Rs 12,600.79 lakhs, marginally lower than Rs 12,764.31 lakhs in FY24. Net profit was Rs 356.29 lakhs versus Rs 359.03 lakhs in the previous year, with basic EPS of Rs 3.11 (vs Rs 3.14). Q4 FY25 was notably stronger with net profit of Rs 223.01 lakhs (up ~47% YoY) on revenue of Rs 3,809.45 lakhs. Operating cash flow more than doubled to Rs 997.62 lakhs (vs Rs 440.09 lakhs). The Board recommended a dividend of Rs 1.5 per share (15%) on 1,14,46,290 equity shares, subject to shareholder approval at the 36th AGM.
For shareholders: a stable full-year performance with a 15% dividend (on a Rs 10 face value) signals consistent shareholder returns, while the strong operating cash flow and EBITDA margin expansion (from ~7.3% to ~9.8%) point to improved profitability, despite the marginal revenue dip. The clean audit opinion and absence of any going-concern or qualification flags are positive for investor confidence.